TELA Bio, Inc. (TELA) Spending and interest coverage
- R&D / revenue · 12 months: Value 11.94%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 11.94% | Research and development expense / revenue. Period ending 2026-06-30. $9.54M ÷ $79.91M × 100 ≈ 11.94% |
| Stock-based compensation / revenue · 12 months | 4.00% | Share-based compensation / revenue. Period ending 2026-06-30. $3.20M ÷ $79.91M × 100 ≈ 4.00% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 9.54M USD | Research and Development Expense |
| Revenue | 79.91M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 3.20M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -34.01M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.54M | $79.91M | $3.20M | $-34.01M | (m) | 11.94% | 4.00% | (m) | (m) |
| 2026-03-31 | $9.02M | $80.81M | $3.57M | $-33.81M | (m) | 11.17% | 4.42% | (m) | (m) |
| 2025-12-31 | $9.22M | $80.28M | $3.80M | $-33.76M | (m) | 11.49% | 4.73% | (m) | (m) |
| 2025-09-30 | $9.12M | $77.06M | $4.07M | $-35.46M | (m) | 11.84% | 5.29% | (m) | (m) |
| 2025-06-30 | $8.84M | $75.32M | $4.20M | $-37.27M | (m) | 11.74% | 5.57% | (m) | (m) |
| 2025-03-31 | $8.96M | $71.22M | $4.30M | $-39.76M | (m) | 12.58% | 6.04% | (m) | (m) |
| 2024-12-31 | $8.81M | $69.30M | $4.36M | $-34.12M | (m) | 12.72% | 6.29% | (m) | (m) |
| 2024-09-30 | $9.47M | $68.65M | $4.51M | $-38.04M | (m) | 13.79% | 6.58% | (m) | (m) |
| 2024-06-30 | $9.77M | $64.74M | $4.80M | $-38.85M | (m) | 15.09% | 7.42% | (m) | (m) |
| 2024-03-31 | $9.96M | $63.15M | $5.01M | $-37.65M | $5.31M | 15.77% | 7.93% | -7.09× | Reported |
| 2023-12-31 | $9.62M | $58.45M | $5.03M | $-44.08M | $5.22M | 16.46% | 8.61% | -8.44× | Reported |
| 2023-09-30 | $9.66M | $53.08M | $4.83M | $-41.24M | $5.05M | 18.20% | 9.10% | -8.16× | Reported |
| 2023-06-30 | $9.39M | $49.18M | $4.49M | $-40.54M | $4.75M | 19.10% | 9.12% | -8.54× | Reported |
| 2023-03-31 | $8.98M | $45.10M | $4.22M | $-40.42M | $4.39M | 19.92% | 9.35% | -9.22× | Reported |
| 2022-12-31 | $8.94M | $41.42M | $3.99M | $-39.01M | $4.05M | 21.58% | 9.63% | -9.63× | Reported |
| 2022-09-30 | $7.94M | $38.17M | $3.77M | $-37.22M | $3.80M | 20.79% | 9.88% | -9.80× | Reported |
| 2022-06-30 | $7.24M | $34.66M | $3.48M | $-34.95M | $3.69M | 20.89% | 10.03% | -9.47× | Reported |
| 2022-03-31 | $7.07M | $31.82M | $3.87M | $-32.03M | $3.62M | 22.22% | 12.16% | -8.85× | Reported |
| 2021-12-31 | $6.74M | $29.46M | $3.66M | $-29.45M | $3.60M | 22.89% | 12.43% | -8.19× | Reported |
| 2021-09-30 | $6.18M | $26.76M | $3.41M | $-28.54M | $3.58M | 23.10% | 12.75% | -7.98× | Reported |
| 2021-06-30 | $5.97M | $24.41M | $3.22M | $-28.19M | $3.55M | 24.46% | 13.19% | -7.93× | Reported |
| 2021-03-31 | $5.02M | $20.36M | $2.30M | $-26.05M | $3.57M | 24.66% | 11.31% | -7.29× | Reported |
| 2020-12-31 | $4.25M | $18.21M | $2.06M | $-25.27M | $3.56M | 23.36% | 11.30% | -7.09× | Reported |
| 2020-09-30 | $4.01M | $17.41M | $1.76M | $-24.35M | $3.54M | 23.05% | 10.11% | -6.87× | Reported |
| 2020-06-30 | $3.33M | $16.07M | $1.28M | $-21.35M | $3.55M | 20.71% | 7.97% | -6.02× | Reported |
| 2020-03-31 | $3.40M | $15.87M | $846.00K | $-20.48M | $3.58M | 21.45% | 5.33% | -5.73× | Reported |
| 2019-12-31 | $4.15M | $15.45M | $457.00K | $-19.16M | $3.61M | 26.87% | 2.96% | -5.31× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.34M | $8.27M | $216.00K | $-17.78M | $1.80M | 52.44% | 2.61% | -9.87× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $5.79M | $4.25M | $197.00K | $-16.92M | $4.56M | 136.30% | 4.64% | -3.71× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| InspireMD, Inc. (NSPR) | $0.033B |